fbpx
News
August 29, 2014

Judge Refuses to Toss $9 Billion Verdict in Pharmaceutical Bellwether Case

In a case that sets the tone for future litigation regarding drugmaker liability, U.S. District Judge Rebecca Doherty in Lafayette, Louisiana rejected a bid by Takeda Pharmaceutical Co. and Eli Lilly & Co. to toss a $9 billion judgment against over claims that the companies did not properly disclose the cancer risks of their Actos medicine.

The jurors in the case deliberated just over an hour before delivering the verdict, which may be the second-largest in the U.S. in 2014.

Both Takeda and Lilly disagree with the ruling citing a 10-year study conducted with the University of Pennsylvania which found no link between the drug and the alleged damages.

The companies have pledged to pursue all remaining avenues, including appeal, at which phase the verdict is likely to be overturned since “the U.S. Supreme Court has said such bad-conduct awards must be proportional to compensatory damage verdicts that underlie them.”

Read the full story here.

stethoscope with books News New Faces Of Lawsuit Abuse Video: Louisiana Medical Professionals Highlight Problems with Trial Lawyer Advertising Class Action Litigation, Medical Liability Video Watch the Recording of ILR Briefly Live Event: COVID-19 State Liability Issues and Solutions Foreign Corrupt Practices Act (FCPA), Medical Liability, Securities Litigation Reform, Telephone Consumer Protection Act (TCPA) Wearing Mask News Plaintiffs' Lawyers Seething Over Push To Limit COVID-19 Related Medical Liability Medical Liability News Protecting Doctors And Nurses On The Front Lines Of This Pandemic From Lawsuits Medical Liability News In The News Today - April 17, 2020 Medical Liability

Cookie Notice

By clicking “I Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

Cookie Notice

By clicking “I Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Review Settings